Aurélien Marabelle
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Immunology top 0.1%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
Papers in
- Oncology 216
- Cancer Immunotherapy and Biomarkers 177
- CAR-T cell therapy research 56
- Colorectal Cancer Treatments and Studies 18
- Immunology 104
- Immunotherapy and Immune Responses 63
- Immune Cell Function and Interaction 42
- Co-authors
- Stephane Champiat (69 shared papers)Jean‐Charles Soria (47 shared papers)laurence ZITVOGEL (17 shared papers)Christophe Massard (45 shared papers)Guido Kroemer (11 shared papers)Roch Houot (13 shared papers)Samy Ammari (28 shared papers)Holbrook E K Kohrt (17 shared papers)
- Journals
- Annals of Oncology (66 papers)European Journal of Cancer (59 papers)Journal for ImmunoTherapy of Cancer (23 papers)Clinical Cancer Research (18 papers)OncoImmunology (11 papers)
- Partner nations
- FranceUnited StatesSpain
In The Last Decade
Aurélien Marabelle
321 papers receiving 29.4k citations
Aurélien Marabelle's Hit Papers
Peers
Comparison fields: 5 of 145
- Oncology 16.4k
- Immunology 8.4k
- Cancer Research 2.6k
- Pulmonary and Respiratory Medicine 4.5k
- Genetics 1.3k
Countries citing papers authored by Aurélien Marabelle
This map shows the geographic impact of Aurélien Marabelle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aurélien Marabelle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aurélien Marabelle more than expected).
Fields of papers citing papers by Aurélien Marabelle
This network shows the impact of papers produced by Aurélien Marabelle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aurélien Marabelle. The network helps show where Aurélien Marabelle may publish in the future.
Co-authors
The 25 scholars most cited alongside Aurélien Marabelle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 336 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study Hit paper breakdown → | 2019 | 2280 |
| 2 | Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study Hit paper breakdown → | 2020 | 1928 |
| 3 | Immune-related adverse events with immune checkpoint blockade: a comprehensive review Hit paper breakdown → | 2016 | 1785 |
| 4 | Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy Hit paper breakdown → | 2016 | 1065 |
| 5 | Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 Hit paper breakdown → | 2016 | 961 |
| 6 | A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study Hit paper breakdown → | 2018 | 959 |
| 7 | Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination Hit paper breakdown → | 2016 | 910 |
| 8 | Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper Hit paper breakdown → | 2015 | 728 |
| 9 | Cancer vaccines: the next immunotherapy frontier Hit paper breakdown → | 2022 | 650 |
| 10 | Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19 Hit paper breakdown → | 2020 | 620 |
| 11 | Mechanisms and therapeutic implications of hypermutation in gliomas Hit paper breakdown → | 2020 | 494 |
| 12 | Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression Hit paper breakdown → | 2021 | 459 |
| 13 | Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors Hit paper breakdown → | 2018 | 446 |
| 14 | Intratumoural administration and tumour tissue targeting of cancer immunotherapies Hit paper breakdown → | 2021 | 389 |
| 15 | Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study Hit paper breakdown → | 2022 | 356 |
| 16 | Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study Hit paper breakdown → | 2022 | 323 |
| 17 | 2013 | 317 | |
| 18 | 2019 | 309 | |
| 19 | 2018 | 301 | |
| 20 | 2017 | 297 |
About Aurélien Marabelle
Aurélien Marabelle is a scholar working on Oncology, Immunology, Cancer Research, Neurology and Pulmonary and Respiratory Medicine, having authored 336 papers that have together received 29.9k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (177 papers), Immunotherapy and Immune Responses (63 papers), CAR-T cell therapy research (56 papers), Immune Cell Function and Interaction (42 papers), Cancer Genomics and Diagnostics (22 papers), Neuroblastoma Research and Treatments (20 papers), Colorectal Cancer Treatments and Studies (18 papers) and Lung Cancer Treatments and Mutations (18 papers). The work is most often cited by research in Oncology (16.4k citations), Immunology (8.4k citations), Cancer Research (2.6k citations), Pulmonary and Respiratory Medicine (4.5k citations) and Genetics (1.3k citations). Aurélien Marabelle has collaborated with scholars based in France, United States and Spain. Frequent co-authors include Stephane Champiat, Jean‐Charles Soria, laurence ZITVOGEL, Christophe Massard, Guido Kroemer, Roch Houot, Samy Ammari, Holbrook E K Kohrt, Caroline Robert and Alexander M.M. Eggermont. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Journal for ImmunoTherapy of Cancer, Clinical Cancer Research and OncoImmunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.